Trotabresib
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 24, 2017 (NCT03220347)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Bromodomain testis-specific proteinINHIBITOR
BRDT inhibitor
- Bromodomain-containing protein 2INHIBITOR
BRD2 inhibitor
- Bromodomain-containing protein 1INHIBITOR
BRD1 inhibitor
- Bromodomain-containing protein 3INHIBITOR
BRD3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(-c2cc(S(C)(=O)=O)ccc2OCC2CC2)c2ccccc2c1=O- Mol. weight
- 383.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650366 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06137651 | Phase 1 | Dec 31, 2023 | National Cancer Institute (NCI), Northwestern University |
| NCT05678283 | Phase 1 | Jan 9, 2023 | Bristol-Myers Squibb |
| NCT04324840 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | Celgene |
| NCT04047303 | Phase 1 | Aug 2, 2019 | Celgene |
| NCT03220347 | Phase 1 | Jul 24, 2017 | Celgene |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 3 | 3 | 2 | 2017 |
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1